CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 400 target
Drug / intervention
LM-108 in combination with Toripalimab +1 moredrug
Likely dose
Paclitaxel injection intravenous infusion 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07362186
NCT07362186Phase 3RecruitingOn Track
CompareCT.gov

A Phase III, Open-Label, Multicenter, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of LM-108 in Combination With Toripalimab Versus Paclitaxel Injection as Second-Line Therapy for CCR8-Positive Locally Advanced or Metastatic Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

LaNova Medicines Limited·interventional·Posted Jan 23, 2026·Updated May 11, 2026

In Brief

A Phase 3 clinical trial evaluating LM-108 in combination with Toripalimab and Paclitaxel injection intravenous infusion for Locally Advanced or Metastatic GC and GCJ Adenocarcinoma. Currently recruiting, targeting 400 participants across 1 site.

Detailed Summary

This is a phase III， Multicenter, Randomized study， evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced or Metastatic GC and GCJ Adenocarcinoma
CountriesChina
Collaborators--

Timeline

Phase 3Recruiting
202620272028
First PostedJan 23, 2026
Enrollment StartApr 30, 2026
Primary CompletionAug 17, 2028
Study CompletionSep 28, 2028
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 5 months agoPrimary completion in 2.1 years

Interventions

LM-108 in combination with Toripalimabdrug

LM-108 combined with Toripalimab administered intravenously on Day 1 every 3 weeks

Paclitaxel injection intravenous infusiondrug

Paclitaxel injection administered at a dose of 80 mg/m² on Day 1, 8, and 15 every 4 weeks